The combination of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) represents the current standard of care for the treatment of advanced ER+ human epidermal growth factor receptor-2 (HER2)-negative BC (aBC). Here, ERBB2 is linked to breast cancer.